Treatment of Diabetic Macular Edema with Intravitreal Antivascular Endothelial Growth Factor and Prompt versus Deferred Focal Laser during Long-Term Follow-Up and Identification of Prognostic Retinal Markers.
Purpose. Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal antivascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics. Methods. Prospective clinical trial (50 treatment-naive eyes) w...
| Publicado en: | Journal of Ophthalmology pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | diagnostic images research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Wiley-Blackwell
10/1/2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132067848&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 132067848 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 2090004X 9038 jtl: Journal of Ophthalmology issn: 2090004X maglogo: N pubinfo: dt: 10/1/2018 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 132067848 132067848 132067848 10.1155/2018/3082560 132067848 ppf: 1 ppct: 11 formats: tig: atl: Treatment of Diabetic Macular Edema with Intravitreal Antivascular Endothelial Growth Factor and Prompt versus Deferred Focal Laser during Long-Term Follow-Up and Identification of Prognostic Retinal Markers. aug: au: Weingessel, Birgit Miháltz, Kata Gleiss, Andreas Sulzbacher, Florian Schütze, Christopher Vécsei-Marlovits, Pia V. affil: Department of Ophthalmology, Hietzing Hospital, Wolkersbergenstrasse 1, Vienna, Austria sug: subj: Diabetes Mellitus Complications Macular Degeneration Etiology Administration, Intraocular Endothelial Growth Factors Administration and Dosage Laser Therapy Long Term Care After Care Biological Markers Macular Degeneration Therapy Macular Degeneration Prognosis Human Randomized Controlled Trials Antibodies, Monoclonal Administration and Dosage Descriptive Statistics Tomography, Optical Coherence Methods Visual Acuity ab: Purpose. Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal antivascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics. Methods. Prospective clinical trial (50 treatment-naive eyes) with DME randomized 1 : 1 receiving intravitreal ranibizumab (0.5 mg/0.05 ml) and prompt grid laser compared with ranibizumab and deferred laser. Morphological characteristics potentially relevant for prognosis were assessed at baseline, month 6, month 9, and years 1, 2, 3, 4, and 5 of follow-up. Results. Although functional results were slightly higher in the prompt group at week 12 (0.5; 20/40 Snellen (SD = 0.04, 0.3 logMAR) versus 0.4; 20/50 Snellen (SD = 0.04, logMAR: 0.4), p=0.4) and month 9 (prompt group: 0.5; 20/40 Snellen (SD = 0.03, 0.3 logMAR) versus deferred group: 0.4; 20/50 Snellen (SD = 0.04, 0.4 logMAR), p=0.4), these were statistically insignificant. There was no significant benefit regarding functionality during long-term follow-up in the prompt group compared to the deferred group. BCVA in the eyes with clusters of hyperreflective foci in the central macular region was inferior compared with the eyes without these alterations at year 5 (0.39; 20/50 Snellen, (SD = 0.25, 0.4 logMAR) versus 0.63; 20/80 Snellen (SD = 0.22, 0.2 logMAR), p<0.01). Conclusion. Grid laser and ranibizumab therapy are effective in DME management during the long-term follow-up. Intraretinal hyperreflective material in SD-OCT is negatively related to BCVA. pubtype: Academic Journal doctype: diagnostic images research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|